Access
To read this story in full you will need to login or make a payment (see right).
Business
Nature 438, 737 (8 December 2005) | doi:10.1038/438737a; Published online 7 December 2005
In brief
In the latest evidence of consolidation in the vaccine industry, the Dutch biotechnology firm Crucell agreed last week to buy the Swiss vaccines company Berna Biotech for 
381 million (US$449 million). The all-share offer, expected to be launched in mid-December, will value Berna shares at a premium of 27% on their closing price on 30 November, the day before the deal was made public.
To read this story in full you will need to login or make a payment (see right).
MORE ARTICLES LIKE THIS
These links to content published by NPG are automatically generated.